Schizophrenia Drug Trial Shows Positive Results

Lundbeck and Otsuka have announced successful results from a Phase 3 clinical trial evaluating the efficacy, safety and tolerability of a once-monthly drug for the treatment of schizophrenia.

Lundbeck and its partner Otsuka have announced successful results from a Phase 3 clinical trial evaluating the efficacy, safety and tolerability of a once-monthly drug for the treatment of schizophrenia.

The study included 710 adult patients with schizophrenia who required chronic treatment with an antipsychotic agent. The 52-week, double-blind trial of aripiprazole intramuscular hit its primary endpoint - to delay the time-to-impending relapse compared to a placebo.

Improvements in symptoms were also maintained throughout the study in patients treated with the drug, while patients who received a placebo reported significantly worsening scores, Lundbeck said in a statem